Several studies have suggested combination therapy with testosterone supplementation in patients not responding to PDE5 inhibitors. Considering the pathophysiological basis for testosterone supplementation, the present study aims to identify whether combination therapy allows persistence of treatment effect after testosterone discontinuation. Furthermore, we evaluated whether the degree of testosterone depletion affects treatment outcome from combination therapy. Hypogonadal patients (o350 ng dl À 1 ) with erectile dysfunction who previously did not respond to PDE5 inhibitors were treated with testosterone enanthate injections and daily tadalafil. Patients were stratified into two groups depending on the level of testosterone deficiency, with 250 ng dl À 1 as a reference point. Following testosterone supplementation (12 weeks) and combination therapy (12 weeks), patients with severe testosterone deficiency showed higher IIEF (International Index of Erectile Function) erectile function (EF) domain score (16.47 ± 4.019 vs 12.36 ± 4.051, P ¼ 0.001) and more patients responding satisfactorily to treatment by general assessment (57.9 vs 16.0%, P ¼ 0.009), despite reaching similar levels of serum total testosterone (602±169 ng dl À 1 vs 698±165 ng dl À 1 , P ¼ 0.057). Testosterone supplementation was then discontinued and patients were maintained only on daily tadalafil (12 weeks). The severe depletion group maintained higher EF domain scores than baseline (13.06 ± 3.38 vs 7.20 ± 2.24, P ¼ 0.0004), despite testosterone levels returning to baseline. The results suggest that combination therapy was more beneficial to patients with severe testosterone depletion, possibly by improving underlying pathophysiology.
INTRODUCTION
Despite the success of PDE5 inhibitors in treating erectile dysfunction, lower treatment rates have been observed for diabetic (64%) and post prostatectomy patients (43%). 1 Hypogonadism has been associated as a common etiological factor, and testosterone replacement in these patients have demonstrated increased responsiveness to PDE5 inhibitors. [2] [3] [4] These studies have shown a general improvement of 34-100%. 5 The question remains whether combination therapy allows fundamental recovery of erectile function. Furthermore, there is a general lack of consensus in researchers as to what construes the state of hypogonadism. Interestingly, some studies have presented that patients with more severe depletion of testosterone showed better response to therapy, and conversely, patients who reached higher testosterone levels during treatment lost treatment benefit. 2 Our study proposed to investigate whether discontinuation of testosterone supplementation allows persistent recovery of PDE5 inhibitor response, and as such, whether patients with severe or intermediate depletion of testosterone benefit more from synergistic effects of testosterone repletion and PDE5 inhibitors.
MATERIALS AND METHODS

Inclusion/exclusion criteria
The study was conducted in accordance with the protocol approved by the Institutional Review Board of Korea University School of Medicine. To be eligible for inclusion in the study, the men were older than 40 years and had a diagnosis of ED, suggestive by an International Index of Erectile Function (IIEF) erectile function (EF) domain score below 22, and at least 3 months treatment with any PDE5 inhibitor, which includes prescriptions of a PDE5 inhibitor equivalent to 100 mg sildenafil. Patients were also primarily included for hypogonadism, as diagnosed by baseline testosterone levels of below 350 ng dl
. Men with Peyronie's disease, penile curvature or with a history of penile surgery other than circumcision were excluded, as were patients who received any form of testosterone supplement in the past. Patients were required to discontinue any PDE5 inhibitors for 2 weeks before entering the study period.
Study design
Patients were divided into two groups, intermediate (o350 ng dl À 1 , X250 ng dl À 1 ) and severe (o250 ng dl À 1 ) deficiency of testosterone based on baseline assessment. Both groups were given the same course of treatment and efficacy and persistence of efficacy following testosterone discontinuation was observed.
The total duration of the study was 36 weeks, divided into three phases of 12 weeks. Phase 1, termed the initiation period, consisted of outpatient visits every 4 weeks for intramuscular testosterone enanthate injection only. This was followed by phase 2, termed the combination treatment period, in which patients continued to receive intramuscular testosterone enanthate injections every 4 weeks, as well as daily tadalafil 5 mg. Phase 3, termed the discontinuation period, consisted of patients receiving daily tadalafil 5 mg only, and discontinuing their testosterone supplementation ( Figure 1 ).
Assessments
Before treatment initiation, and at the termination of each 12-week phase, baseline and treatment efficacy was assessed by the IIEF 15-item questionnaire, validated and translated into Korean. The primary efficacy measure was assessed by the EF domain score. Secondary measures included the Sexual Encounter Profile Question 2 (SEP2: Were you able to insert your penis into your partner's vagina?) and Question 3 (SEP3: Did your erection last long enough for you to complete intercourse with ejaculation?), and patient responses to the Global Assessment Question (GAQ: Has the treatment you have been taking over the past study interval improved your erections?). Blood tests for total testosterone and free testosterone was performed at initiation and at the end of phases 2 and 3.
Statistical methods
Factors associated with treatment success were assessed at completion of combination therapy and at completion of study. The initial variables examined at enrollment were compared between treatment success and failure groups. Statistical analyses were performed with P-values o0.05 being considered significant. Statistical analyses were computed with R (v 2.12. 
RESULTS
Overall patient characteristics A total of 46 men (age range 41-75 years) comprised the study cohort. Twenty patients showed serum testosterone levels below 250 ng dl À 1 (severe group) and 26 patients showed testosterone levels above 250 ng dl À 1 (intermediate group). Patients with one or more comorbidities comprised 91.3% (n ¼ 42). The most prevalent condition was diabetes, (n ¼ 18, 39.1%), followed by prostatic hyperplasia (n ¼ 16, 34.8%) and hypertension (n ¼ 10, 21.7%). Although all 4 patients with no significant medical history showed intermediate levels of testosterone deficiency, there was no significant predominance of comorbidities between the two groups ( Table 1) .
Only 2 patients dropped out during combination therapy, and 10 more patients dropped out after testosterone was discontinued, with only 73.9% (34 out of 46) completing the entire study duration. While a total of seven patients were lost during followup for unknown reasons, five patients requested removal from study complaining of lack of treatment benefits. Overall patient characteristics and characteristics by cohort divided by degree of testosterone deficiency is presented in Table 1 ( Figure 1 ).
Effect of combination therapy (V3)
The initial EF domain scores showed no significant difference between the two groups (P ¼ 0.16). Effect of combination therapy was estimated for patients who maintained treatment by the 24th week (N ¼ 44). Both severe and intermediate groups showed improvement in EF domain scores. The severe group showed Testosterone levels observed at this point was 602 ± 169 ng dl
and 698 ± 165 ng dl
, respectively, for severe and intermediate groups (P ¼ 0.057). Although no patient showed significant supraphysiological levels of testosterone, two patients in the severe group and one patient in the intermediate group showed serum testosterone level below 350 ng dl À 1 ( Figure 3) . Overall, 18 patients (34.1%) reported improvement based on GAQ, with 57.9% (11 out of 19) from the severe group and 16.0% (4 out of 25) (P ¼ 0.009). Response to SEP2 and SEP3 questions also showed similar tendencies, with 13 patients (68.4%) from the severe group and 7 patients (28.0%) from the intermediate group responding positive to the SEP2 question (P ¼ 0.014), and 12 patients (63.2%) from the severe group and 2 patients (8.0%) from the intermediate group responding positive to the SEP3 question (Po0.001) (Figure 4 ). Persistent effects of combination therapy (V4) Persistent effects of treatment was estimated for patients who maintained treatment until the 36th week (N ¼ 34). Effects were estimated by comparison with initial EF domain score values. The severe group showed a higher EF score maintained by the end of study with 13.06 ± 3.38, compared with 9.53 ± 3.11 for the intermediate group (P ¼ 0.0045). Furthermore, the EF domain scores for the intermediate group was not significantly different than the initial values (P ¼ 0.5879), whereas the scores for the severe group was different from initial values (P ¼ 0.0004). However, no patient showed EF domain score values above 20. (Figure 2) Testosterone levels observed at this point was 212±78 ng dl
for the severe group, and 263±117 ng dl À 1 for the intermediate group (P ¼ 0.102). While all patients in the severe group returned to testosterone levels below 350 ng dl À 1 , 6 patients in the intermediate group showed normal testosterone levels. However, when compared with their initial values, both groups showed no significant change in testosterone levels (P ¼ 0.05 for severe group; P ¼ 0.33 for intermediate group) (Figure 3) .
Overall, four patients (11.8%) maintained based on GAQ; all patients were from the severe group (23.5%) (P ¼ 0.103). Figure 2 . Patients with severe testosterone deficiency achieved higher treatment response estimated by IIEF (International Index of Erectile Function) erectile function (EF) domain score (V2, V3). These patients also maintained elevated response after discontinuation of testosterone supplementation (V4). **Po0.01, ***Po0.001. Figure 3 . Both groups achieved similar levels of serum testosterone with testosterone supplementations (V3). After termination of testosterone enanthate injections, both groups showed return to pretreatment levels of serum testosterone (V4). **Po0.01, ***Po0.001.
Similar tendencies were also observed with response to SEP2 and SEP3 questions; five patients (29.4%) from the severe group and two patients (11.8%) from the intermediate group responded positive to the SEP2 question (P ¼ 0.398); three patients (17.6%) from the severe group and no patient from the intermediate group responded positive to the SEP3 question (P ¼ 0.227) (Figure 4 ).
DISCUSSION
The present study was an observational study of two cohort groups treated for a prolonged period with testosterone and daily tadalafil. The primary objective was to identify persistent treatment effects of testosterone replacement on erectile function. Previous studies have shown that testosterone supplementation provides structural change of erectile tissue, leading to functional improvement evident by decrease of venous leakage. 6, 7 It may be hypothesized that supplementation of deficient testosterone may provide restorative properties to these tissues, which may also be evident even when testosterone is discontinued. Our results show that patients who were more severely deficient in testosterone maintained better function after discontinuation of testosterone supplementation. Although presence of actual structural regeneration of erectile tissue has not been evaluated, it is notable that the duration between termination of testosterone supplementation and measurement of final outcome (12 weeks) was significantly longer than documented testosterone level decline to after intramuscular injection of testosterone enanthate. 8 These outcomes were stratified between patients with severe and intermediate levels of hypogonadism, as theoretically testosterone replacement could be hypothesized to be less efficacious where hypogonadism was not primarily severe. Previous studies also suggested combination therapy to be effective only to proven hypogonadal patients. [2] [3] [4] [5] 7, 9 While both severe and intermediate levels of testosterone deficiency achieved significant increases in EF domain scores, patients who had severe testosterone deficiency achieved higher increase than patients who had intermediate deficiency, despite achieving similar levels of serum testosterone. These results implicate a different underlying pathophysiology of erectile dysfunction in these two patient groups. Testosterone deficiency alone is rarely the main or single cause of ED. 10 Several studies have noted reciprocal effects between chronic disorders, such as diabetes, hypertension, obesity, metabolic syndrome and dyslipidemia. [11] [12] [13] [14] How severe these disorders affect erectile function cannot easily be stratified, although unresponsiveness of these patients have been attributed to progression to a more severe vascular disease, either by diabetic or untreated hypertension, leading to microvascular or macrovascular complications that deter erection, which may or may not present concomitant deficiency of testosterone. 13, 15 Significant pathology of the erectile tissue may be refractory to repletion of testosterone, especially if the deficiency is already not so marked. Various factors may be involved in the actual responsiveness to testosterone depending on the individuals. 5, 16 Studies have suggested that factors besides apparent serum testosterone levels, such as androgen receptor sensitivity, may not only vary among individuals but also significantly affect presentation of comorbidities, which may in turn affect erectile function. 17, 18 The persistent and higher response shown in the group with severe deficiency may represent patients in whom testosterone deficiency functions as the primary debilitating factor of erectile dysfunction. Conversely, the intermediate group may paradoxically represent patients with other dysfunctional elements that could not be alleviated with testosterone replacement, and may have more significant comorbidities, which deter treatment response.
The current study also aimed to identify whether such differing benefits may eventually affect persistence of the restorative effects possibly gleaned from testosterone supplementation in these deficient patients. Previous studies have shown that testosterone supplementation provides structural change of erectile tissue, leading to functional improvement evident by decrease of venous leakage. 6, 7 It may be hypothesized that supplementation of deficient testosterone may provide restorative properties to these tissues, which also may be evident even when testosterone is discontinued. Our results show that patients who were more severely deficient in testosterone maintained better function after discontinuation of testosterone supplementation. Although presence of actual structural regeneration of erectile tissue is debatable, it is notable that the duration between termination of testosterone supplementation and measurement of final outcome (12 weeks) was significantly longer than documented testosterone level decline to after intramuscular injection of testosterone enanthate. 8 Testosterone enanthate is an oil-based injectable steroid, designed to slowly release testosterone from the injection site. Once administered, serum concentrations have been shown to rise for several days and remain markedly elevated for 2 weeks, fully diminishing at 3 weeks. The decision behind the choice of selecting testosterone enanthate over testosterone gel, preferred in similar studies, 2,3 was made to maintain an effective regimen for long-term therapy, which required increased patient compliance by minimizing the number of interventions and clinical visits, but more importantly to avoid side effects from supraphysiological levels of testosterone. As evident by previous dosage studies, testosterone enanthate maintains a relatively constant serum level. 19 While most dosing schedules dictate injection every 3 weeks, our patient group maintained slightly lower, but normal, mean levels of testosterone during supplementation, with no patients showing supraphysiological levels and only three patients failing to achieve 350 ng dl À 1 . No patients reported side effects or complications from treatment. Furthermore, only two patients were lost during treatment up to 24 weeks and all remaining patients showed good compliance to treatment. Thus, the protocol of injecting testosterone enanthate every 4 weeks avoids side effects while maintaining a stable supplementation of serum testosterone at normal levels. In practice, patients failing to achieve normalization may be selectively managed to an altered injection schedule of every 3 weeks.
The overall subjective cure rate, as assessed by the GAQ at the end of combination therapy, was 34.1%. This was lower than 34B100% reported in other studies. [2] [3] [4] In part, there is a notable difference in patient selection. The study by Kalinchenko et al. 4 recruited only diabetic patients, whereas other studies failed to mention the prevalence of comorbidities. 3 Another difference is with the mode of testosterone delivery. Shabsigh et al. 2 and Greenstein et al.
3 used daily testosterone gel, whereas Kalinchenko et al. 4 used twice daily oral testosterone undecanoate (120 mg per day). As our study used testosterone enanthate injections every 4 weeks, this may have led to lower sustained levels of testosterone. As, in our study, testosterone levels were measured at trough levels before injection, the level of plasma total testosterone is not fully comparable. However, with repeated injections for 24 weeks, the average total serum testosterone was 656±172 ng dl À 1 , and 698±165 ng dl À 1 even for patients with initial total testosterone below 250 ng dl À 1 . Furthermore, the success rate was 57.9%, and similar to previous reports, for patients with severe testosterone deficiency.
Finally, the study size was comparable to previous studies, while observing treatment effects for a significantly longer period. 3, 20, 21 This resulted in some difficulty in maintaining patient compliance during longer periods when testosterone supplementation was discontinued, as several patients with intermediate testosterone levels found PDE5 inhibitor monotherapy lacked treatment benefits.
In conclusion, the present study showed different treatment benefits of combination therapy with testosterone and PDE5 inhibitors between severe and intermediate testosterone-deficient patients who are refractory to PDE5 inhibitor monotherapy. Furthermore, the present combination therapy of testosterone enanthate and daily tadalafil shows a safe and effective treatment regimen.
